Home >> Marketplace Directory >> FDA clears CytoScan Dx, 3/14

FDA clears CytoScan Dx, 3/14

image_pdfCreate PDF

March 2014—Affymetrix received FDA 510(k) clearance to market its CytoScan Dx assay, intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. Cyto­Scan Dx is designed to help diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution, genome-wide analysis of genetic aberrations.

Affymetrix, 408-731-5523

CAP TODAY
X